Current Neurology and Neuroscience Reports

, Volume 11, Issue 2, pp 227–234 | Cite as

Hypocretin and Its Emerging Role as a Target for Treatment of Sleep Disorders

Article

Abstract

The neuropeptides hypocretin-1 and -2 (orexin A and B) are critical in the regulation of arousal and maintenance of wakefulness. Understanding the role of the hypocretin system in sleep/wake regulation has come from narcolepsy-cataplexy research. Deficiency of hypocretin results in loss of sleep/wake control with consequent unstable transitions from wakefulness into non–rapid eye movement (REM) and REM sleep, and clinical manifestations including daytime hypersomnolence, sleep attacks, and cataplexy. The hypocretin system regulates sleep/wake control through complex interactions between monoaminergic/cholinergic wake–promoting and GABAergic sleep–promoting neuronal systems. Research for the hypocretin agonist and the hypocretin antagonist for the treatment of sleep disorders has vigorously increased over the past 10 years. This review will focus on the origin, functions, and mechanisms in which the hypocretin system regulates sleep and wakefulness, and discuss its emerging role as a target for the treatment of sleep disorders.

Keywords

Hypocretin Orexin Narcolepsy Cataplexy Sleep Wakefulness Hypothalamus Insomnia Arousal Almorexant 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    de Lecea L, Kilduff TS, Peyron C, et al.: The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998; 95: 322–327.PubMedCrossRefGoogle Scholar
  2. 2.
    Sakurai T, Amemiya A, Ishii M, et al.: Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998; 92: 573–585.PubMedCrossRefGoogle Scholar
  3. 3.
    Marcus JN, Aschkenasi CJ, Lee CE, et al.: Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 2001; 435: 6-25.PubMedCrossRefGoogle Scholar
  4. 4.
    Date Y, Ueta Y, Yamashita H, et al.: Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc Natl Acad Sci U S A 1999; 96: 748–753.PubMedCrossRefGoogle Scholar
  5. 5.
    •• Ohno K, Sakurai T: Orexin neuronal circuitry: role in the regulation of sleep and wakefulness. Front Neuroendocrinol 2008; 29: 70–87. This article discusses the mechanisms by which orexin regulates sleep and wakefulness, as well as other systems including behavior, feeding, reward, and total body energy homeostasis. PubMedCrossRefGoogle Scholar
  6. 6.
    Willie JT, Chemelli RM, Sinton CM, et al.: Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron 2003; 38: 715–730.PubMedCrossRefGoogle Scholar
  7. 7.
    Saper CB, Chou TC, Scammell TE: The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci 2001; 24: 726–731.PubMedCrossRefGoogle Scholar
  8. 8.
    Steininger TL, Alam MN, Gong H, et al.: Sleep-waking discharge of neurons in the posterior lateral hypothalamus of the albino rat. Brain Res 1999; 840: 138–147.PubMedCrossRefGoogle Scholar
  9. 9.
    El Mansari M, Sakai K, Jouvet M: Unitary characteristics of presumptive cholinergic tegmental neurons during the sleep-waking cycle in freely moving cats. Exp Brain Res 1989; 76: 519–529.PubMedCrossRefGoogle Scholar
  10. 10.
    Szymusiak R, Alam N, Steininger TL, McGinty D: Sleep-waking discharge patterns of ventrolateral preoptic/anterior hypothalamic neurons in rats. Brain Res 1998; 803: 178–188.PubMedCrossRefGoogle Scholar
  11. 11.
    Yoshida K, McCormack S, Espana RA, et al.: Afferents to the orexin neurons of the rat brain. J Comp Neurol 2006; 494: 845–-861.PubMedCrossRefGoogle Scholar
  12. 12.
    Sakurai T, Nagata R, Yamanaka A, et al.: Input of orexin/hypocretin neurons revealed by a genetically encoded tracer in mice. Neuron 2005; 46: 297–308.PubMedCrossRefGoogle Scholar
  13. 13.
    •• Arrigoni E, Mochizuki T, Scammell TE: Activation of the basal forebrain by the orexin/hypocretin neurones. Acta Physiol (Oxf) 2010; 198: 223–235. This article discusses the mechanisms by which hypocretin excites cholinergic BF neuronal systems to promote cortical activation. Findings from this study suggest that the BF may be a key site through which hypocretin activates the cortex to promote arousal. CrossRefGoogle Scholar
  14. 14.
    Fadel J, Pasumarthi R, Reznikov LR: Stimulation of cortical acetylcholine release by orexin A. Neuroscience 2005; 130: 541–547.PubMedCrossRefGoogle Scholar
  15. 15.
    Eggermann E, Serafin M, Bayer L, et al.: Orexins/hypocretins excite basal forebrain cholinergic neurones. Neuroscience 2001; 108: 177–181.PubMedCrossRefGoogle Scholar
  16. 16.
    Yamanaka A, Muraki Y, Tsujino N, et al.: Regulation of orexin neurons by the monoaminergic and cholinergic systems. Biochem Biophys Res Commun 2003; 303: 120–129.PubMedCrossRefGoogle Scholar
  17. 17.
    Takahashi K, Lin JS, Sakai K: Neuronal activity of orexin and non-orexin waking-active neurons during wake-sleep states in the mouse. Neuroscience 2008; 153: 860–870.PubMedCrossRefGoogle Scholar
  18. 18.
    Fujiki N, Yoshida Y, Ripley B, et al.: Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep 2003; 26: 953–959.PubMedGoogle Scholar
  19. 19.
    Vogel V, Sanchez C, Jennum P: EEG measurements by means of radiotelemetry after intracerebroventricular (ICV) cannulation in rodents. J Neurosci Methods 2002; 118: 89–96.PubMedCrossRefGoogle Scholar
  20. 20.
    Xi MC, Morales FR, Chase MH: Effects on sleep and wakefulness of the injection of hypocretin-1 (orexin-A) into the laterodorsal tegmental nucleus of the cat. Brain Res 2001; 901: 259–264.PubMedCrossRefGoogle Scholar
  21. 21.
    Methippara MM, Alam MN, Szymusiak R, McGinty D: Effects of lateral preoptic area application of orexin-A on sleep-wakefulness. Neuroreport 2000; 11: 3423–3426.PubMedCrossRefGoogle Scholar
  22. 22.
    Bourgin P, Huitron-Resendiz S, Spier AD, et al.: Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J Neurosci 2000; 20: 7760–7765.PubMedGoogle Scholar
  23. 23.
    Huang ZL, Qu WM, Li WD, et al.: Arousal effect of orexin A depends on activation of the histaminergic system. Proc Natl Acad Sci U S A 2001; 98: 9965–9970.PubMedCrossRefGoogle Scholar
  24. 24.
    Brevig HN, Watson CJ, Lydic R, Baghdoyan HA: Hypocretin and GABA interact in the pontine reticular formation to increase wakefulness. Sleep 2010; 33: 1285–1293.PubMedGoogle Scholar
  25. 25.
    Horvath TL, Gao XB: Input organization and plasticity of hypocretin neurons: possible clues to obesity’s association with insomnia. Cell Metab 2005; 1: 279–286.PubMedCrossRefGoogle Scholar
  26. 26.
    Rao Y, Liu ZW, Borok E, et al.: Prolonged wakefulness induces experience-dependent synaptic plasticity in mouse hypocretin/orexin neurons. J Clin Invest 2007; 117: 4022–4033.PubMedCrossRefGoogle Scholar
  27. 27.
    Yamanaka A, Beuckmann CT, Willie JT, et al.: Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron 2003; 38: 701–713.PubMedCrossRefGoogle Scholar
  28. 28.
    •• Gao XB, Wang AH: Experience-dependent plasticity in hypocretin/orexin neurones: re-setting arousal threshold. Acta Physiol (Oxf) 2010; 198: 251–262. This article summarizes recent evidence supporting the theory that hypocretin neurons undergo neuronal spasticity in relation to changes in internal and external environmental factors, and consequently changing or resetting the arousal threshold. CrossRefGoogle Scholar
  29. 29.
    Lin L, Faraco J, Li R, et al.: The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999; 98: 365–376.PubMedCrossRefGoogle Scholar
  30. 30.
    Chemelli RM, Willie JT, Sinton CM, et al.: Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999; 98: 437–451.PubMedCrossRefGoogle Scholar
  31. 31.
    Nishino S, Ripley B, Overeem S, et al.: Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000; 355: 39–40.PubMedCrossRefGoogle Scholar
  32. 32.
    Peyron C, Faraco J, Rogers W, et al.: A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000; 6: 991–997.PubMedCrossRefGoogle Scholar
  33. 33.
    Thannickal TC, Moore RY, Nienhuis R, et al.: Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000; 27: 469–474.PubMedCrossRefGoogle Scholar
  34. 34.
    Crocker A, Espana RA, Papadopoulou M, et al.: Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 2005; 65: 1184–1188.PubMedCrossRefGoogle Scholar
  35. 35.
    Honda M, Eriksson KS, Zhang S, et al.: IGFBP3 colocalizes with and regulates hypocretin (orexin). PLoS One 2009; 4: e4254.PubMedCrossRefGoogle Scholar
  36. 36.
    Hara J, Beuckmann CT, Nambu T, et al.: Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001; 30: 345–354.PubMedCrossRefGoogle Scholar
  37. 37.
    Mieda M, Willie JT, Hara J, et al.: Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A 2004; 101: 4649–4654.PubMedCrossRefGoogle Scholar
  38. 38.
    •• Willie JT, Takahira H, Shibahara M, et al.: Ectopic Overexpression of Orexin Alters Sleep/Wakefulness States and Muscle Tone Regulation during REM Sleep in Mice. J Mol Neurosci. 2010 [Epub ahead of print]. This article describes the mechanisms in which hypocretin regulates sleep and wakefulness, as well as the importance of how it is regulated to have normal maintenance of sleep and waking states. Overexpression of hypocretin alters sleep/wakefulness and muscle tone regulation resulting in incomplete muscle atonia of REM sleep. Google Scholar
  39. 39.
    • Hallmayer J, Faraco J, Lin L, et al.: Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 2009; 41: 708–711. This article discusses the first genome-wide association study on narcolepsy leading to the discovery that narcolepsy is strongly associated with polymorphisms in the T-cell receptor-α locus, encoding a major receptor for the HLA peptide presentation in any disease. PubMedCrossRefGoogle Scholar
  40. 40.
    Nishino S: Clinical and neurobiological aspects of narcolepsy. Sleep Med 2007; 8: 373–399.PubMedCrossRefGoogle Scholar
  41. 41.
    • Dhuria SV, Hanson LR, Frey WH, 2nd: Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system. J Pharm Sci 2009; 98: 2501–2515. This article describes the effectiveness of intranasal administration of hypocretin agonist to the CNS. To date, intranasal administration is the only mode of administration that holds promise in delivering hypocretin agonist for potential treatment of narcolepsy. PubMedCrossRefGoogle Scholar
  42. 42.
    Hallschmid M, Born J: Revealing the potential of intranasally administered orexin A (hypocretin-1). Mol Interv 2008; 8: 133–137.PubMedCrossRefGoogle Scholar
  43. 43.
    Foundation NS: Sleep in America poll. Data from 2002, 2003, 2004, and 2005 sleep polls. Washington D.C.; 2005.Google Scholar
  44. 44.
    •• Brisbare-Roch C, Dingemanse J, Koberstein R, et al.: Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 2007; 13: 150–155. This article describes the first dual hypocretin receptor antagonist and discussed results of preclinical and clinical trials. Results of this study opened new perspectives for further investigation of hypocretin antagonist in sleep/wake regulation. PubMedCrossRefGoogle Scholar
  45. 45.
    •• Hoever P, de Haas S, Winkler J, et al.: Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. Clin Pharmacol Ther 2010; 87: 593–600. This article discusses the clinical trial of almorexant, the first dual hypocretin receptor antagonist tested in healthy subjects for the treatment of insomnia. The trial evaluated tolerability, pharmacokinetics, and pharmacodynamics of this drug. PubMedCrossRefGoogle Scholar
  46. 46.
    Dingemanse J DG, Goran H, Benes H, et al.: Proof-of-concept study in primary insomnia patients with ACT-078573, a dual orexin receptor antagonist. Sleep Biol Rhythms 2007: A194.Google Scholar
  47. 47.
    Cox CD, Breslin MJ, Whitman DB, et al.: Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methy l-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem 2010; 53: 5320–5332.PubMedCrossRefGoogle Scholar
  48. 48.
    Malherbe P, Borroni E, Gobbi L, et al.: Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX (2) receptor. Br J Pharmacol 2009; 156: 1326–1341.PubMedCrossRefGoogle Scholar
  49. 49.
    • Han F, Mignot E, Wei YC, et al.: Ventilatory chemoresponsiveness, narcolepsy-cataplexy and human leukocyte antigen DQB1*0602 status. Eur Respir J 2010; 36: 577–583. This article describes evidence that hypocretin influences chemosensitivity, and responses to hypercapnia and hypoxia. Significance of this finding in relation to sleep-disordered breathing is of further interest. PubMedCrossRefGoogle Scholar
  50. 50.
    Li A, Nattie E: Antagonism of rat orexin receptors by almorexant attenuates central chemoreception in wakefulness in the active period of the diurnal cycle. J Physiol 2010; 588: 2935–2944.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Stanford University Sleep MedicineRedwood CityUSA

Personalised recommendations